Stock Analysis on Net

Eli Lilly & Co. (NYSE:LLY)

$24.99

Debt to Equity
since 2005

Microsoft Excel

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Calculation

Eli Lilly & Co., debt to equity, long-term trends, calculation

Microsoft Excel

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

1 US$ in thousands


The financial data reveals several key trends regarding the company's debt structure and equity base over the period analyzed. The total debt shows considerable fluctuation, with an initial decline from 6.5 billion USD at the end of 2005 to approximately 3.7 billion USD in 2006, followed by notable volatility in subsequent years. Significant peaks are observed in 2008, 2015, and 2023, ultimately resulting in the highest value of approximately 33.6 billion USD by 2024.

Shareholders’ equity exhibits a generally upward trend from 2005 to 2007, growing from roughly 10.8 billion USD to 13.7 billion USD. However, this is interrupted by a sharp decrease in 2008 to around 6.7 billion USD. Thereafter, equity figures fluctuate, with some recovery observed through 2012 but declining again until 2019, when a substantial dip to about 2.6 billion USD occurs. From 2020 onwards, the equity base recovers steadily, reaching around 14.2 billion USD by 2024.

The debt to equity ratio demonstrates significant variability over the period. Initially decreasing from 0.6 in 2005 to 0.34 in 2006 and stabilizing around 0.3 to 0.7 between 2006 and 2012, the ratio rises sharply in 2013 and especially in 2019, where it peaks dramatically at 5.88. Subsequent years show a gradual reduction but remain elevated relative to early-period levels, ending at approximately 2.37 in 2024. This indicates a substantial increase in leverage, particularly pronounced during the 2019 period, which reflects an increase in debt levels relative to equity.

Overall, the data indicates a company that has undergone significant shifts in its capital structure, marked by periods of increased leverage and fluctuating equity levels. The most notable pattern is the sharp increase in debt around the late 2010s into the early 2020s, accompanied by variable equity performance. The elevated debt to equity ratios in recent years suggest increased financial risk relative to earlier periods, warranting close monitoring of debt management and equity growth going forward.

Total Debt
Fluctuated notably with peaks especially in 2008, 2015, and from 2023 onward, culminating in a peak of approximately 33.6 billion USD in 2024.
Shareholders’ Equity
Generally increased until 2007, then declined significantly by 2008, followed by oscillations and a pronounced dip in 2019, with recovery observed post-2020.
Debt to Equity Ratio
Varied widely from 0.34 in 2006 to a peak of 5.88 in 2019, indicating increasing leverage and financial risk over time, remaining elevated above early decade levels through 2024.

Comparison to Competitors

Eli Lilly & Co., debt to equity, long-term trends, comparison to competitors

Microsoft Excel

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)

Eli Lilly & Co., debt to equity, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)

Microsoft Excel

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Comparison to Industry (Health Care)